These statements are based on a press release statement and are forward-looking, involving risks and uncertainties that could cause actual results to differ materially from those projected. While analysts maintain a positive outlook with price targets ranging from $9 to $10, Elicio's future plans for ELI-002 and its other product candidates are subject to a variety of factors, including the availability of future financing and the outcomes of ongoing clinical trials. For comprehensive financial analysis and real-time updates on ELTX and other biotech opportunities, consider subscribing to InvestingPro. The findings, presented at the ESMO Immuno-Oncology Congress 2024, revealed a median recurrence-free survival (mRFS) of 16.3 months and a median overall survival (mOS) of 28.9 months across the study population.
These statements are based on a press release statement and are forward-looking, involving risks and uncertainties that could cause actual results to differ materially from those projected. While analysts maintain a positive outlook with price targets ranging from $9 to $10, Elicio's future plans for ELI-002 and its other product candidates are subject to a variety of factors, including the availability of future financing and the outcomes of ongoing clinical trials. For comprehensive financial analysis and real-time updates on ELTX and other biotech opportunities, consider subscribing to InvestingPro. The updated data, with a median follow-up of 19.7 months, indicated that ELI-002 elicited mKRAS-specific T cell responses in most patients and was well-tolerated without any severe treatment-emergent adverse events.
Patients who exhibited above-median T cell responses have not yet reached the mRFS threshold, while those with below-median responses recorded a 4.0-month mRFS. Both the pancreatic cancer subgroup and the full cohort shared an identical 28.9-month mOS, which compares favorably to historical controls.
Dr. Christopher Haqq, Elicio's EVP and Chief Medical (TASE:PMCN) Officer, expressed optimism about the continued positive performance of ELI-002 and the strong correlation between T cell response and reduced risk of disease progression. He anticipates the interim analysis of the randomized Phase 2 trial expected in the first half of 2025.
Elicio's ELI-002, which targets the most common KRAS mutations found in approximately 25% of all solid tumors, is part of the company's efforts to develop off-the-shelf vaccines for high-prevalence cancers. The company's proprietary Amphiphile (AMP (OTC:AMLTF)) technology is designed to enhance the delivery of cancer vaccines to lymph nodes, potentially leading to stronger and more durable immune responses.
These statements are based on a press release statement and are forward-looking, involving risks and uncertainties that could cause actual results to differ materially from those projected. While analysts maintain a positive outlook with price targets ranging from $9 to $10, Elicio's future plans for ELI-002 and its other product candidates are subject to a variety of factors, including the availability of future financing and the outcomes of ongoing clinical trials. For comprehensive financial analysis and real-time updates on ELTX and other biotech opportunities, consider subscribing to InvestingPro.
In other recent news, Elicio Therapeutics has made significant strides in its clinical trials and executive team appointments. The biotech firm has completed patient enrollment for its Phase 2 study of ELI-002, a novel immunotherapy aimed at treating pancreatic cancer. The company has also reported encouraging preliminary results from its Phase 1 AMPLIFY-7P clinical trial of the same cancer vaccine.
In analyst news, Elicio Therapeutics received a Buy rating from Jones Trading, highlighting the potential of the company's cancer vaccine candidate. However, the company's annual stockholders' meeting was adjourned due to the absence of a quorum, with the reconvened meeting scheduled for later.
Recent developments within Elicio Therapeutics also include executive changes. Robert Connelly has been appointed as the Principal Accounting Officer and Principal Financial (NASDAQ:PFG) Officer, following the resignation of CFO and Treasurer, Brian Piekos. In terms of financial moves, the company is planning to raise approximately $11.5 million through an underwritten public offering. These are the latest developments in the company's ongoing efforts to pioneer effective cancer immunotherapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.